Answers are grounded in this paper and cite their sources.
Randomized trial evaluates carbon footprint of semaglutide in type 2 diabetes, suggesting environmental benefits.
OBJECTIVE: To evaluate the carbon footprint and clinical outcomes of once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2DM) in the United Kingdom. METHODS: Using the IQVIA Core Diabetes Model, environmental and clinical impacts were projected over a lifetime horizon from the National Health Services perspective. Data from the SUSTAIN-2 (patients with T2DM) and SUSTAIN-6 (patients with T2DM and established cardiovascular [CV] risk) trials were used to compare semaglutide with sitagliptin and placebo, respectively. Outcomes included life expectancy measured in life-years (LYs), and quality-adjusted life expectancy measured in quality-adjusted life-years (QALYs) gained; incidence of diabetes-related complications and adverse events; carbon emissions; and incremental carbon footprint effectiveness ratios (ICFERs). RESULTS: was mainly driven by reduced complications and treatment needs. Sensitivity analyses supported the robustness of the results. CONCLUSION: Semaglutide offers environmental advantages over sitagliptin for patients with T2DM overall and over standard of care for those with established CV risk.
No takes yet. Share an insight, caveat, or question.
Lund et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: